Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 20/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 0.73 |
| ▸ | DRD2 | P14416 | 1/20 | 0.73 |
| ▸ | DRD1 | P21728 | 1/20 | 0.73 |
| ▸ | HTR2A | P28223 | 1/20 | 0.73 |
| ▸ | HTR2C | P28335 | 1/20 | 0.73 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.73 |
| ▸ | HTR6 | P50406 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL2987143 | 0.99 | HTR7 (0.98) | HTR7HTR1ADRD2DRD1HTR2A | |
| SCHEMBL2990951 | 0.94 | HTR7 (1.00) | HTR7HTR1ADRD2DRD1HTR2A | |
| SCHEMBL2976258 | 0.92 | HTR7 (1.00) | HTR7 | |
| SCHEMBL2980860 | 0.92 | HTR7 (0.87) | HTR7HTR1ADRD2DRD1HTR2A | |
| SCHEMBL2975652 | 0.91 | HTR7 (1.00) | HTR7HTR1ADRD2DRD1HTR2A | |
| SCHEMBL4015368 | 0.91 | HTR7 (0.89) | HTR7HTR1ADRD2DRD1HTR2A | |
| SCHEMBL2976306 | 0.90 | HTR7 (0.87) | HTR7 | |
| SCHEMBL4013094 | 0.90 | HTR7 (1.00) | HTR7 | |
| SCHEMBL2974166 | 0.89 | HTR7 (0.94) | HTR7 | |
| SCHEMBL27662805 | 0.89 | HTR7 (1.00) | HTR7HTR1ADRD2DRD1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1993324-B | 3-(((4-phenyl)-piperazin-1-yl)-alkyl)-3-alkyl-1,3-dihydro-2h-indol-2-one derivatives and related compounds for the treatment of central nervous system disorders | EGYT GYOGYSZERVEGYESZETI GYAR | 2010-12-15 | — | — | CN | claimed |
| US-7786129-B2 | Piperazine derivatives of dialkyl oxindoles | EGIS GYOGYSZERGYAR NYRT (HU) | 2010-08-31 | — | — | US | claimed |
| EP-1776339-B1 | 3-(((4-PHENYL)-PIPERAZIN-1-YL)-ALKYL)-3-ALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | EGIS GYOGYSZERGYAR NYRT (HU) | 2009-07-01 | — | — | EP | claimed |
| US-20070232619-A1 | Piperazine Derivatives of Dialkyl Oxindoles | EGIS GYOGYSZERGYAR RT. (HU) | 2007-10-04 | — | — | US | claimed |
| CN-1993324-A | 3-(((4-phenyl)-piperazin-1-yl)-alkyl)-3-alkyl-1,3-dihydro-2h-indol-2-one derivatives and related compounds for the treatment of central nervous system disorders | EGIS GYOGYSZERGYAR NYRT (HU) | 2007-07-04 | — | — | CN | claimed |
| EP-1776339-A2 | 3-(((4-PHENYL)-PIPERAZIN-1-YL)-ALKYL)-3-ALKYL-1,3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | EGIS Gyógyszergyár Nyrt (HU) | 2007-04-25 | — | — | EP | claimed |
| WO-2005109987-A9 | 3-(((4-PHENYL)-PIPERAZINE-1-YL)-ALKYL)-3-ALKYL-1, 3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | EGIS GYOGYSZERGYAR NYRT (HU) | 2007-03-29 | — | — | WO | claimed |
| WO-2005109987-A2 | 3-(((4-PHENYL)-PIPERAZINE-1-YL)-ALKYL)-3-ALKYL-1, 3-DIHYDRO-2H-INDOL-2-ONE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS | EGIS GYÓGYSZERGYÁR NYRT. (HU) | 2005-11-24 | — | — | WO | claimed |
| CN-1993324-B | 3-(((4-phenyl)-piperazin-1-yl)-alkyl)-3-alkyl-1,3-dihydro-2h-indol-2-one derivatives and related compounds for the treatment of central nervous system disorders | EGYT GYOGYSZERVEGYESZETI GYAR | 2010-12-15 | — | — | CN | disclosed |
| CN-1993324-A | 3-(((4-phenyl)-piperazin-1-yl)-alkyl)-3-alkyl-1,3-dihydro-2h-indol-2-one derivatives and related compounds for the treatment of central nervous system disorders | EGIS GYOGYSZERGYAR NYRT (HU) | 2007-07-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232619-A1 | Piperazine Derivatives of Dialkyl Oxindoles | TPH2, DRD3, CNR2 | HTR7 35/4885HTR1A 102/4885DRD2 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.